BioSpace News Archive

EOM Pharmaceuticals, Inc., a privately held, clinical-stage company, today announced the appointment of Frank L. Douglas , Ph.D., M.D., to Scientific Advisor.

Athenex, Inc. today announced that the Company will provide a corporate and financial update for the second quarter 2021, on Thursday, August 5, 2021, before the market opens.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that the US Food & Drug Administration (FDA) has granted a new Certificate of Free Sale for Tollovid Daily™, the newest member of the Company’s Tollovid™ dietary supplement product line.

Moderna, Inc. today announced a new supply agreement with Taiwan for 20 million doses of Moderna’s COVID-19 vaccine and its updated variant booster vaccine candidate, if authorized, to begin delivery in 2022 and an additional 15 million doses in 2023.

PharmaCyte Biotech, Inc. (OTCQB: PMCBD), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that three independent industry publications mention PharmaCyte and/or its past clinical trials and their contributions to prior and future work in the treatment of pancreatic cancer.

RedHill Biopharma Ltd. today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP (“AstraZeneca”) and Nektar Therapeutics have entered into a settlement and license agreement with Apotex, Inc. resolving their patent litigation.

EV Biologics Corp., announced that it has signed a Letter of Intent with Lonza Cell & Gene Therapy for Process Development and Gap Analysis for biomanufacturing of a novel therapeutic composition, comprising extracellular vesicles and particles, as well as other secreted factors derived from selected stem/progenitor cells, such as mesenchymal stromal cells.

JanOne Inc. today announced that it has selected CPC Clinical Research (CPC),a full-service academic research organization (ARO), as manager for its upcoming Phase 2b clinical trial of lead product candidate JAN101 for treating Peripheral Artery Disease (PAD).

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that it has been awarded a grant from the National Institute on Drug Abuse of the National Institutes of Health to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use.

The hypertrophic and keloid scar treatment market was valued at US$ 4,498.99 million in 2019 and is projected to reach US$ 9,972.69 million by 2027; it is expected to grow at a CAGR of 10.6% from 2020 to 2027.